These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35452102)

  • 21. Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant.
    Müller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Söderdahl G; Smith CIE; Loré K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren HG; Österborg A; Sette A; Grifoni A; Aleman S; Buggert M
    Cell Host Microbe; 2024 Feb; 32(2):156-161.e3. PubMed ID: 38211584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
    Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
    Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals.
    Naranbhai V; Nathan A; Kaseke C; Berrios C; Khatri A; Choi S; Getz MA; Tano-Menka R; Ofoman O; Gayton A; Senjobe F; Denis KJS; Lam EC; Garcia-Beltran WF; Balazs AB; Walker BD; Iafrate AJ; Gaiha GD
    medRxiv; 2022 Jan; ():. PubMed ID: 35018386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
    Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2-specific T cell responses: a comparative analysis between QuantiFERON SARS-CoV-2, T-SPOT.COVID, and an in-house Omicron ELISpot.
    Mak WA; Visser W; Koeleman JGM; Ong DSY
    J Virol Methods; 2024 Jun; 327():114949. PubMed ID: 38710307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant.
    Liu J; Chandrashekar A; Sellers D; Barrett J; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
    medRxiv; 2022 Jan; ():. PubMed ID: 35018387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity.
    Riou C; Keeton R; Moyo-Gwete T; Hermanus T; Kgagudi P; Baguma R; Valley-Omar Z; Smith M; Tegally H; Doolabh D; Iranzadeh A; Tyers L; Mutavhatsindi H; Tincho MB; Benede N; Marais G; Chinhoyi LR; Mennen M; Skelem S; du Bruyn E; Stek C; ; de Oliveira T; Williamson C; Moore PL; Wilkinson RJ; Ntusi NAB; Burgers WA
    Sci Transl Med; 2022 Feb; 14(631):eabj6824. PubMed ID: 34931886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity.
    Joung SY; Ebinger JE; Sun N; Liu Y; Wu M; Tang AB; Prostko JC; Frias EC; Stewart JL; Sobhani K; Cheng S
    JAMA Netw Open; 2022 Aug; 5(8):e2227241. PubMed ID: 35976645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults.
    Kared H; Wolf AS; Alirezaylavasani A; Ravussin A; Solum G; Tran TT; Lund-Johansen F; Vaage JT; Nissen-Meyer LS; Nygaard UC; Hungnes O; Robertson AH; Næss LM; Trogstad L; Magnus P; Munthe LA; Mjaaland S
    Nat Commun; 2022 Jul; 13(1):4165. PubMed ID: 35851055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy.
    Novazzi F; Baj A; Genoni A; Focosi D; Maggi F
    Emerg Infect Dis; 2022 Jun; 28(6):1301-1302. PubMed ID: 35416767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Passerini M; Ratishvili T; Monroe JM; Temesgen Z; Witzig TE; Kay NE; Kennedy RB; Parikh SA
    Leuk Lymphoma; 2023 Apr; 64(4):874-883. PubMed ID: 36908110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant.
    Tian D; Sun Y; Xu H; Ye Q
    J Med Virol; 2022 Jun; 94(6):2376-2383. PubMed ID: 35118687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.